Member Info for Dr_DMS

Is this based on a currently approved drug like AVA6000 or completely new?

Several analysts have set their target to $25-28 now...

https://www.marketbeat.com/instant-alerts/nyse-ccl-percent-advance-2024-10-08/

I wouldn't bother doing anything with any AIM companies WB, complete waste of time, they are all the same

Dr Gezim Lahu ref 3 on the poster

Gary - I hope not, said a cash deal and dividends are currently at rock bottom

https://www.riotinto.com/en/invest/shareholder-information/dividends/dividend-history-and-calculator

Working with the ex Takeda global head i see...

Like I said, cheap offer, seems they doubled it!

Actually, better than any Avacta presentation as it's explained in laymans terms.

One thing that wasn't mentioned though, was that the lack of severe cardio toxicity opens up the possibility to treat over 65 year olds, that are currently not allowed to be treated with doxorubicin.

Things like that open up the scope for AVA6000 and precision massively.

Maybe they think that they can just buy in someone elses PCR machine as orders are placed and therefore reduce costs....

Novacyt seems unable to sell anything anymore

Looks like a cheap offer, doubt they will accept it, but you never know....!

Have they sold Dx then?

Yeh ive been in NCYT 4 yrs now and made nothing, so gonna try trading it now

And no news on pipeline... must start within the next few days as said multiple news flows between now and the roadshow

GLA :)

Exactly!! Just games all the time with this share! Although they could do with paying some debt down...

How many of these tests are IVD......? Sounds like most are RUO to me

Problem is, to do the R&D you need millions and millions to fund it......

It doesn't matter which way you do it, they can't afford to be choosy, just need some cash coming in now!

No target price?

They haven't said they are doing breast cancer